Nuvectis Pharma (NVCT) Research & Development (2021 - 2026)
Nuvectis Pharma (NVCT) posted Research & Development of $4.1 million for Q1 2026, down 19.27% sequentially from $5.1 million in Q4 2025, and up 11.58% YoY from $3.7 million in Q1 2025.
Nuvectis Pharma (NVCT) Research & Development (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Research & Development for 6 years, with the latest figure at $4.1 million in Q1 2026.
- Quarterly Research & Development rose 11.58% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.6 million (up 33.3% YoY) and the FY2025 annual result came in at $18.2 million, up 40.52% from the prior year.
- Research & Development slipped to $4.1 million in Q1 2026 per NVCT's latest filing, from $5.1 million in the prior quarter.
- Over five years, Research & Development peaked at $5.8 million in Q3 2025 and troughed at $865000.0 in Q1 2022.
- A 5-year average of $3.7 million and a median of $4.1 million in 2026 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 284.35% in 2022, down 40.99% in 2022.
- Over 5 years, Research & Development stood at $4.4 million in 2022, then slipped by 3.0% to $4.3 million in 2023, then rose by 5.42% to $4.5 million in 2024, then advanced by 13.12% to $5.1 million in 2025, then slipped by 19.27% to $4.1 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $4.1 million, $5.1 million, and $5.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | 4.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.68 Mn |
| Mar 31, 2026 | 4.11 Mn |
| Dec 31, 2025 | 5.09 Mn |
| Sep 30, 2025 | 5.77 Mn |
| Jun 30, 2025 | 3.61 Mn |
| Mar 31, 2025 | 3.68 Mn |
| Dec 31, 2024 | 4.50 Mn |
| Sep 30, 2024 | 2.82 Mn |
| Jun 30, 2024 | 2.94 Mn |
| Mar 31, 2024 | 2.66 Mn |
| Dec 31, 2023 | 4.27 Mn |
| Sep 30, 2023 | 4.49 Mn |
| Jun 30, 2023 | 4.26 Mn |
| Mar 31, 2023 | 2.37 Mn |
| Dec 31, 2022 | 4.40 Mn |
| Sep 30, 2022 | 4.52 Mn |
| Jun 30, 2022 | 2.51 Mn |
| Mar 31, 2022 | 865,000.00 |
| Dec 31, 2021 | 1.14 Mn |
| Sep 30, 2021 | 4.16 Mn |